Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 18, 2026
Can you apply?
This grant is for research on cancer risk mechanisms related to incretin mimetics (diabetes medications). NIH R01 grants support independent, investigator-initiated biomedical and behavioral research projects.
Eligible applicants include researchers at academic institutions, hospitals, government agencies, and nonprofits with research capacity. Applicants must have a research doctorate or equivalent and demonstrate research experience. U.S. citizenship or permanent residency is typically required.
This award supports original research using human subjects, clinical trials optional. Projects examining how incretin mimetics affect cancer risk pathways are within scope. The program is open nationally with no geographic restrictions.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- SF-424 (R&R) application form
- Project Narrative (Research Strategy)
- Detailed Budget and Budget Justification
- Biographical Sketches (PI and Key Personnel)
- Letters of Support from participating institutions
- Institutional Certification on vertebrate animals or human subjects (if applicable)
- IRB or IACUC approval documentation
- Preliminary Studies and Progress Report
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.393 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$213,206,023
-
$56,551,552
-
$48,640,472
-
$47,009,863
-
$42,878,192
-
$37,448,862
-
$29,324,004
-
$26,395,336
-
$24,427,436
-
$23,149,727
Top States by Funding
- MA 10 awards $374.4M
- CA 10 awards $260.1M
- MN 4 awards $106.9M
- NY 7 awards $99.9M
- TN 7 awards $97.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.393). How funding has trended year over year.
| 2024 | $754,945,159 | |
| 2025 | $834,514,512 | |
| 2026 est. | $520,096,276 |
FAQ
Who is eligible to apply?
Researchers with a doctoral degree (Ph.D., M.D., D.D.S., or equivalent) at research institutions. Your institution must have an active Federal Negotiated Indirect Cost Rate Agreement.
Is a clinical trial required?
No. The grant is titled "Clinical Trial Optional," so you may propose laboratory research, mechanistic studies, or other designs without human subjects.
What is the typical funding range?
NIH R01 grants typically fund $200,000–$500,000 annually for 3–5 years, but this varies by field and project scope.
When is the deadline?
The application deadline is January 7, 2027. Submit at least 24 hours before 5 p.m. ET to allow for submission errors.
How competitive is this grant?
NIH R01 grants are highly competitive. Plan for rigorous scientific design, preliminary data, and alignment with NIH priorities on cancer prevention and metabolic disease.
💡 Tips for applicants
- Build your case with strong preliminary data showing a plausible mechanism linking incretin mimetics to cancer risk.
- Clearly specify whether you will include human subjects; if yes, explain clinical trial design and regulatory approvals.
- Address both the scientific innovation and public health significance of understanding this drug–cancer relationship.
- Include a detailed timeline with clear milestones and measurable outcomes for each project year.
- Use your specific aims section to focus on 2–4 distinct, achievable research questions that together tell a cohesive story.
⚠️ Common mistakes
Weak or absent preliminary data is the leading reason applications are rejected. Reviewers need evidence your approach works.
Vague or overly broad research aims reduce competitiveness. Define specific hypotheses and measurable endpoints clearly.
Misaligned biosketches or lack of prior cancer/metabolic disease publications raise concerns about research expertise fit.
Similar grants
- OPEN Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) — National Institutes of Health
- OPEN Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) — National Institutes of Health